Insulin resistance is a recognized feature of PCOS (polycystic ovary syndrome). However, the molecular reason(s) underlying this reduced cellular insulin sensitivity is not clear. The present study compares the major insulin signalling pathways in skeletal muscle isolated from PCOS and controls. We measured wholebody insulin sensitivity and insulin signalling in skeletal muscle biopsies taken before and after acute exposure to hyperinsulinaemia in nine women diagnosed with PCOS and seven controls. We examined the expression, basal activity and response to in vivo insulin stimulation of three signalling molecules within these human muscle samples, namely IRS-1 (insulin receptor substrate-1), PKB (protein kinase B) and ERK (extracellularsignal-regulated kinase) 1/2. There was no significant difference in the expression, basal activity or activation of IRS-1 or PKB between PCOS and control subjects. However, there was a severe attenuation of insulin stimulation of the ERK pathway in muscle from all but two of the women with PCOS (the two most obese), and an accompanying trend towards higher basal phosphorylation of ERK1/2 in PCOS. These results are striking in that the metabolic actions of insulin are widely believed to require the IRS-1/ PKB pathway rather than ERK, and the former has been reported as defective in some previous PCOS studies. Most importantly, the molecular defect identified was independent of adiposity. The altered response of ERK to insulin in PCOS was the most obvious signalling defect associated with insulin resistance in muscle from these patients.
INTRODUCTION
PCOS (polycystic ovary syndrome) is a common endocrine disorder affecting up to 10% of women of reproductive age. The central features of this heterogeneous disorder are hyperandrogenism, oligomenorrhoea and infertility, with obesity in up to 60 % of patients [1, 2] . Women with PCOS exhibit peripheral insulin resistance similar in magnitude to that seen in T2DM (Type 2 diabetes mellitus) [3, 4] ; this is reported to be independent of BMI (body mass index), but is clearly exacerbated by associated obesity. Forty percent of obese women with PCOS develop impaired glucose tolerance, with up to 10 % developing T2DM [5] [6] [7] [8] [9] [10] . Insulin resistance is believed to be critical to the pathophysiology of the disorder, with the use of insulin-sensitizing agents such as metformin, thiazolidinediones and diazoxide widely recognized to confer therapeutic benefits [11] . The high risk of progression from insulin resistance to T2DM associated with PCOS may indicate that the two diseases share a common molecular defect [12, 13] ; however, the molecular reason(s) for impaired insulin action in either disease remains unclear.
The two best characterized insulin signalling pathways are the Ras-ERK (extracellular-signal-regulated kinase) pathway and the IRS (insulin receptor substrate)-PKB (protein kinase B) pathway. The actions of these two pathways are diverse, with the Ras-ERK pathway primarily mediating mitogenic effects, and the metabolic actions of insulin primarily requiring the IRS-PKB pathway. Activation of the oncogene Ras, which ultimately leads to stimulation of ERK1/2 (for a review, see [14] ), promotes expression of immediate early genes involved in growth and proliferation. This pathway also regulates a diverse range of transcription factors and signalling molecules that are likely to be involved in more widespread cellular processes. Activation of the IRS-PKB pathway is initiated by the phosphorylation of IRS proteins by the insulin receptor tyrosine kinase [15] . This leads to activation of PI3K (phosphoinositide 3-kinase) and downstream targets including PKB, often called Akt) [16] [17] [18] . Activated PKB is involved in many actions of insulin such as regulation of glucose transport [19, 20] , gluconeogenesis [21] and glycogen synthesis [22] , but this pathway also controls aspects of growth and apoptosis [23] .
In T2DM, there is evidence that insulin signalling is defective at the level of IRS-1, due to negative regulation of this protein by high fatty acid and triacylglycerol (triglyceride) levels [24] [25] [26] [27] [28] . The negative regulation involves increased serine/threonine phosphorylation of IRS-1 at a number of residues [29] [30] [31] , resulting in ubiquitination and subsequent degradation of the IRS-1 protein [26] . Indeed, some studies report defective IRS signalling in the muscle of insulin-resistant volunteers [32] , whereas disruption of IRS-2 in mice results in diabetes [33] . Molecular signalling has been studied in cultured skin fibroblasts, adipocytes, myotubes, theca cells and skeletal muscle biopsies from patients with PCOS [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] . The data are somewhat conflicting, but overall suggest impaired metabolic signalling (IRS-PKB) and enhanced, or intact, mitogenic signalling (Ras-ERK).
Indeed, the evidence suggests that distinct signalling problems may exist in different insulin-responsive tissues [47] .
The aim of the present study was to investigate the activation state of these two major insulin signalling pathways in skeletal muscle biopsies in response to experimental hyperinsulinaemia in vivo, in women with and without PCOS. We hypothesized that a clear molecular defect underlying resistance to insulin-mediated glucose uptake would be detectable in muscle from women with PCOS.
EXPERIMENTAL

Materials
Antibodies against phospho-PKB (Ser 473 ), phospho-ERK1/2 (Thr 202 /Tyr 204 ), and total ERK1/2 were from Cell Signaling Technology. Those for IRS-1 and total PKB were from Upstate Biotechnologies, and the anti-β-actin antibody was purchased from Sigma-Aldrich.
Methods
Local Ethical Committee approval was obtained for the study and written informed consent was obtained from all participants.
Subjects
Female volunteers with PCOS (Rotterdam Criteria; [48] ) without a history of diabetes or impaired glucose tolerance attending the combined Gynaecology/Endocrinology Infertility Clinic of Ninewells Hospital, a tertiary referral centre, were invited to participate. Ten women with PCOS were recruited, though on further assessment one subject was not included in the study as she did not fulfil the diagnostic criteria. The criteria used for the diagnosis of PCOS included oligo/amenorrhoea (six or fewer menstrual cycles in the previous year), elevation of serum total testosterone and/or free androgen index 2 S.D. greater than the reference range established in the local laboratory, and polycystic ovarian morphology on transvaginal ultrasound scan [49] . Women attending the Gynaecology clinic for sterilization were invited to participate as control subjects, their numbers being supplemented by newspaper advertisement. Eight controls were recruited to the study. One control subject experienced approx. 5 min of asymptomatic hypoglycaemia (< 2.0 mmol/l) due to loss and re-establishment of venous access during her second muscle biopsy and was not included in the study. Seven controls were therefore included in the data analysis. Six of the control subjects had regular menstrual cycles, no evidence of hirsutism and normal ovarian morphology on transvaginal ultrasound scan. The seventh control subject was amenorrhoeic as she was using the Levonorgestrel intrauterine system for contraception, but had a history of regular menstrual cycles, no hirsutism and normal ovarian morphology on scan. Besides this subject, none of the controls or subjects with PCOS were on any sex steroid hormone treatment. The subjects were not on any medications or diet known to alter carbohydrate metabolism for at least 3 months prior to the study.
Assays LH (luteinizing hormone), FSH (follicle-stimulating hormone), oestradiol, progesterone and testosterone were measured by chemiluminometric immunoassays using a Roche Modular SWA (E170 unit) in conjunction with Roche calibrators and reagents. SHBG (sex hormone-binding globulin) and insulin were measured by chemiluminometric immunoassays using a Siemens IMMULITE 2000 analyser in conjunction with Siemens calibrators and reagents. The free androgen index was calculated from testosterone and SHBG [(testosterone/SHBG) × 100].
Total cholesterol, HDL (high-density lipoprotein)-cholesterol, triacylglycerols and glucose were measured by photometric assays using a Roche Modular SWA (P800 unit) in conjunction with Roche calibrators and reagents. LDL (low-density lipoprotein)-cholesterol was calculated from total cholesterol, and HDLcholesterol and triacylglycerols by means of the Friedewald formula (this was not applied to samples with serum triacylglycerols greater than 4.0 mmol/l).
Assessment of insulin sensitivity
All subjects underwent an ITT (insulin tolerance test) following an overnight fast, as previously described [50, 51] . The parameter K itt , derived from the slope of plasma glucose values in response to a weight-adjusted insulin bolus during the linear decline of plasma glucose (t = 3-15 min), has been shown to correlate highly with the M-value derived from the 'gold standard' method for insulin sensitivity measurement, the hyperinsulinaemiceuglycaemic clamp (counter regulatory hormone responses occur at t = 15-20 min) [52] . Intravenous cannulae were inserted into right and left antecubital veins, one for blood sampling and the other for administration of insulin and glucose. Venous blood was collected every 3 min during the study period for bedside assessment of plasma glucose (Yellowsprings YSI 2300) with concomitant sampling for later assay of plasma insulin. After baseline blood sampling, Actrapid insulin 0.1 unit/kg of body weight (NovoNordisk) was administered at time t = 0 min. A slow saline infusion was maintained through that line for infusion of 10 % dextrose solution at the end of the study, or earlier according to predefined 'rescue' hypoglycaemia plasma glucose criteria.
Calculation of insulin sensitivity
K itt insulin sensitivity was calculated from the slope of leastsquare analysis of the plasma glucose analysis between t = 3 and t = 15 min (expressed as the percentage fall/min) [50] .
Human skeletal muscle extraction
Forceps biopsies were taken according to established procedures from the right vastus lateralis muscle prior to insulin exposure (basal) [53] . A second biopsy was taken from a different incision on the same leg, at t = 15-20 min (insulin stimulated). Muscle biopsies were snap frozen in liquid nitrogen.
Preparation of protein extracts for Western blotting
Protein extracts were obtained as described previously [53] . In brief, muscle biopsies were thawed on ice and homogenized (Dounce, 10-15 strokes) in 0.5 ml of ice-cold lysis buffer [25 mM Tris/HCl (pH 7.4), 50 mM NaF, 100 mM NaCl, 1 mM sodium vanadate, 5 mM EGTA, 1 mM EDTA, 1 % (v/v) Triton X-100, 10 mM sodium pyrophosphate, 0.27 M sucrose, complete protease inhibitor tablets (1 tablet/10 ml) and 0.1 % (v/v) 2-mercaptoethanol]. Lysates were obtained from the supernatant fraction after 10 min centrifugation at 10 000 g, and then pre-cleared for 1 h at 4
• C with Protein G-Sepharose in 50 % (v/v) PBS. This process removed contaminating antibodies present due to variable amounts of blood in the muscle samples. Potential contamination of muscle protein lysate with adipose protein was measured by the ratio of troponin C to FABP (fatty acid binding protein) 4 in every lysate, and in no case was there significant contamination (results not shown).
Western blot analysis
Protein extracts (30-40 μg) were separated on Novex SDS 4-12 % polyacrylamide gels. Following transfer to nitrocellulose, blots were blocked with 5 % (w/v) non-fat dried skimmed milk in TBST [Tris-buffered saline (20 mM Tris/HCl and 150 mM NaCl) containing 0.1 % Tween 20] for 1 h, and then incubated with primary antibodies at 4
• C overnight, prior to incubation for 1 h at room temperature (20 • C) with secondary antibody and development using ECL (enhanced chemiluminescence; Amersham Biosciences). Insulin treatment of cells induces the phosphorylation of ERK1/2 at Tyr 187 and Thr 185 (numbers relate to the human ERK2 sequence) [54] , and this dual phosphorylation activates the enzyme. Hence a phosphospecific antibody to this motif (P-ERK) provides a measure of the activity status of ERK1/2 [45] . PKB is activated by phosphorylation on two residues, namely Thr 308 and Ser
473
(for review, see [16] [17] [18] ). Phosphorylation of both residues is required for PKB activation, therefore, an increase in Ser 473 phosphorylation is often used as a surrogate marker of activation. Phosphorylation status was assessed by the ratio of phosphorylated-to-total protein for ERK1/2 and PKB. Protein loading was assessed by β-actin measurement, and IRS-1 levels were corrected for loading.
Quantification
Protein bands were scanned and quantified by densitometry using AIDA Image Analyser software.
Statistical methods SPSS version 9.15 and MINITAB ® statistical software (Release 15) was used to perform most of the data handling and data analysis. Results are reported as the mean response + − S.E.M. For some of the quantities measured, variation increased markedly with central location; these quantities were analysed on a logarithmic scale to help stabilize variation. The principal procedure used to test the hypothesis of no difference between the mean responses in the two populations (i.e. the control and the PCOS populations) was the two independent sample Student's t test using an adjustment to the degrees of freedom to allow for unequal variances. For the results of the test procedure to be meaningfully interpreted and applied generally, the sampling procedure used to select the subjects must be assumed to introduce no biases.
RESULTS
Demographic characteristics of the nine women with PCOS and seven healthy control subjects (all Caucasian) are shown in Tables 1 and 2 . Thyroid function tests, prolactin and 17-OHP (17-hydroxyprogesterone) levels were within normal limits for all participants. None of the women had evidence of impaired fasting glucose, although one control had a first-degree relative with T2DM.
There were no statistically significant differences in weight or adiposity between the healthy and PCOS groups. Although control subjects were not fully matched to PCOS women for obesity, neither group was clinically obese (BMI 25.4 compared with 29.8 kg/m 2 , P = 0.072). Neither the fasting blood glucose (4.5 compared with 4.4 mmol/l, P = 0.73) nor the insulin levels (6.7 compared with 18 m-units/l, P = 0.055) were significantly different between the groups. However, the PCOS patients were more insulin resistant, with a lower K itt (4.8 compared with 3.2 %/min, P = 0.024). The insulin area under the curve during the ITT was similar in the two groups (Tables 1 and 2 ). The mean time interval between insulin bolus and second biopsy in control subjects was 15.6 (1.2) min [mean (S.E.M.)] and that for PCOS was 18.3 (1.1) min (P = 0.117). The mean insulin measurement at the time of second biopsy in controls was 91 (13.3) m-units/l and that for PCOS was 109.8 (16.3) m-units/l (P = 0.393). The regulation of the key signalling molecules, PKB, ERK and IRS-1 by insulin was assessed by immunoblot ( Figure 1) . We attempted to measure other facets of signalling, however the signal-to-noise ratio was too weak to provide conclusive results, either due to the time point being studied, or the quality of available reagents. There was a trend towards higher basal ERK phosphorylation in the PCOS samples (Figure 2A compared with 2B), however this was not statistically significant ( Figure 2C ). We found that insulin increased the ratio of phospho-ERK to total ERK in five out of the seven control volunteers, whereas ERK phosphorylation was actually reduced in most of the nine volunteers with PCOS (Figures 2A and 2B ). Most strikingly, there was a significant difference in the average level of induction of ERK by insulin between controls and PCOS subjects (2.04 compared with 0.71, P < 0.05; Figure 2C ).
Figure 1 Representative immunoblots for analysis of IRS-1, PKB and ERK
Protein lysate (30 mg) prepared from muscle biopsies isolated from control and PCOS volunteers, after an overnight fast (−), or from the same individual after a 20 min exposure to insulin (+), were subjected to SDS/PAGE, transferred on to nitrocellulose and analysed using specific antibodies as indicated. Reactive species were visualized by ECL. Con, control; p473-PKB, phosphorylated PKB (on Ser 473 ).
Figure 2 Assessment of ERK activity
Immunoblots of seven control and nine PCOS muscle biopsies, before and after exposure to insulin for 20 min, were quantified. The ratio of phospho-ERK to total ERK (P:T) was determined for every biopsy and that ratio is shown for the control (A) and PCOS (B) volunteers, before (basal) and after insulin for each individual. In addition, the mean + − S.E.M. fasted and post-insulin ratios for each group are given (C), along with the mean + − S.E.M. fold change in ERK phosphorylation (C).
Ser
473 phosphorylation was higher in the post-insulin biopsy in all but two volunteers ( Figures 3A and 3B) . The average induction of Ser 473 phosphorylation for both groups was approx. 4-fold ( Figure 3C ). One healthy volunteer, and one volunteer with PCOS, had comparatively high basal Ser 473 phosphorylation, and in both cases subsequent exposure to insulin did not stimulate Ser 473 phosphorylation. There was no significant difference in Ser 473 phosphorylation between the two groups either before or
Figure 3 Analysis of PKB activity
Immunoblots of seven control and nine PCOS muscle biopsies, before and after exposure to insulin for 20 min, were quantified. The ratio of phospho-PKB to total PKB (P:T) was determined for every biopsy and that ratio is shown for the control (A) and PCOS (B) volunteers, before (basal) and after insulin for each individual. In addition, the mean + − S.E.M. fasted and post-insulin ratios for each group are given (C), along with the mean + − S.E.M. fold change in PKB phosphorylation (C).
after insulin injection, or a significant difference in the degree of induction following insulin between groups ( Figure 3C ).
IRS-1 protein levels are reported to be reduced in muscle from insulin-resistant individuals with T2DM, and we have previously observed a 2-3-fold induction of IRS-1 protein levels following exposure of healthy muscle to insulin in vivo [53] . In both healthy (3.1-fold, Figure 4A ) and PCOS (5.3-fold, Figure 4B ) groups, there was a significant induction of IRS-1 following exposure to insulin. Indeed, all but one of the volunteers had increased IRS-1
Figure 4 Analysis of IRS-1 expression
Immunoblots of seven control and nine PCOS muscle biopsies, before and after exposure to insulin for 20 min, were quantified. The ratio of IRS-1 to β-actin was determined for every biopsy and that ratio is shown for the control (A) and PCOS (B) volunteers, before (basal) and after insulin for each individual. In addition, the mean + − S.E.M. fasted and post-insulin ratios for each group are given (C), along with the mean + − S.E.M. fold change in IRS-1 levels (D).
in the post-insulin biopsy. There was a great deal of variation in basal expression of IRS-1 between individuals (Figures 1 and  4) , however there was no significant difference in expression of IRS-1 between control and PCOS muscle, either in the fasted or post-insulin states ( Figure 4C ). Similarly, average induction of IRS-1 by insulin was not significantly different between groups ( Figure 4D ). There was no correlation between BMI and the defective regulation of ERK in the PCOS group ( Figure 5A) . Indeed, the only two PCOS volunteers that showed some ability to activate ERK in response to insulin had two of the highest BMI values of the group ( Figure 5A ). Nevertheless, we performed a subanalysis where the three PCOS subjects with the highest BMI were omitted, resulting in a fall in the average BMI of the group to 27.6 kg/m 2 (P = 0.37 when compared with the control group). Despite the smaller sample size, the insulin regulation of ERK in this leaner PCOS group remained significantly different from the control group (0.589 + − 0.27, P = 0.034 compared with control). In order to investigate the effect of BMI further, we regrouped all of the volunteers (control and PCOS) into low ( 27 kg/m 2 ) or high (> 27 kg/m 2 ) BMI cohorts. Insulin activation of ERK was lower in the high-BMI group; although this did not reach statistical significance ( Figure 5B ), this simple analysis argues against BMI as the factor driving the differences in ERK activation observed in the PCOS group. Importantly, while the high-BMI group activated ERK relatively weakly in response to insulin, the PCOS group generally exhibited reduced ERK phosphorylation after insulin administration (Figure 2) .
DISCUSSION
Discovering the molecular defect underlying insulin resistance in specific tissues in distinct insulin-resistant states should allow a more accurate diagnosis and directed targeting of interventions. The results of the present study are novel in that they clearly implicate the ERK pathway in insulin resistance in intact muscle from women with PCOS for the first time. In particular, we observed reduced ERK activity in skeletal muscle following exposure to insulin with almost all PCOS subjects, contrasting with the physiological increase in ERK activity expected in response to insulin. It remains to be determined whether the defect in the ERK pathway that we have observed in intact muscle tissue is conserved in other insulin-sensitive tissues such as adipose and liver, or in the insulin-sensitive cells of the ovary. Loss of insulin regulation of ERK has only been reported previously in tumour cells lacking PTEN (phosphatase and tensin homologue deleted on chromosome 10) (which opposes the action of PI3K), and in these cells the effect on the ERK pathway was much more dramatic than the effect on the PI3K-PKB pathway [55] .
Much of the early work on insulin signalling in PCOS was performed in cultured skin fibroblasts [34] [35] [36] [37] [38] . The results suggested increased phosphorylation of serine residues of the insulin receptor in cultured fibroblasts isolated from PCOS skin. This was accompanied by reduced tyrosine phosphorylation of the receptor, indicative of reduced receptor signalling [34] . Despite this, downstream activation of PKB was normal in the fibroblasts from PCOS [37] . There are no reports on the regulation of ERK in these cells.
In contrast, phosphorylation and expression of the insulin receptor in more 'classical' insulin target tissues (adipose and muscle) appeared comparatively normal [39, 40] . However, in cultured adipocytes from PCOS subjects, tyrosine phosphorylation and expression of IRS-1 was reduced [41] . Interestingly, reduced GLUT4 (glucose transporter 4) expression was also reported in adipocytes from PCOS, and this (like the present study) was independent of obesity [43] .
We have focused our work on insulin regulation of muscle, as this is the major tissue involved in insulin-stimulated glucose disposal. Previous work in cultured human myotubes provided evidence for slightly higher IRS-1 levels in cells isolated from PCOS muscle, compared with control cells, as well as a 2-fold induction of phosphorylation of Ser 312 of IRS-1 [44] . Interestingly, IRS-1-associated PI3K activity was reduced in the PCOS cells when a correction was made for the increased IRS-1 level [44] . However, PKB and ERK activities were not measured.
Signalling analysis in cells cultured from isolated muscle is not consistent with in vivo analysis of signalling in human PCOS muscle. Two previous studies have analysed insulin action in intact PCOS muscle [40, 45] . Dunaif et al. [40] found increased IRS-2, but not IRS-1, expression in intact muscle, suggestive of a difference in the PCOS-associated defect between intact muscle, isolated myoblasts and adipose (where IRS-2 appeared normal; [42] ). However, in both cultured muscle cells and intact muscle, IRS-1 signalling was reduced (measured by PI3K-associated activity) with PCOS, but PKB activation was not assessed. Most recently, Hojlund et al. [46] reported small reductions in IRS-1-PKB responses to insulin in intact muscle, and the reduced signalling could be reversed by treatment with insulin-sensitizing agents. We could not detect abnormalities in PKB activation by insulin, suggesting a relatively normal IRS-1-PI3K response in PCOS muscle, at least at the insulin concentration and time point used in the present study. The study protocols do differ slightly in that we have used an ITT to assess insulin sensitivity and initiate signalling events, as opposed to a hyperinsulinaemiceuglycaemic clamp. In addition, the mean BMI of the PCOS subjects in the present study was much lower (29.8 kg/m 2 ). Basal phosphorylation of ERK has been previously reported to be significantly higher in isolated PCOS muscle compared with controls [45] , but the insulin response was not reported. These are in agreement with our observation of a trend towards increased basal ERK phosphorylation in PCOS muscle ( Figure 2C ). Although insulin regulation of ERK has not been previously analysed in PCOS in vivo, a high basal and insulin-stimulated activity of the pathway, downstream of Ras, was observed in cultured myotubes from PCOS compared with controls [45] . Abnormally high ERK activity has also been seen in theca cells from subjects with PCOS [56] , although this was linked to abnormal androgen production rather than response to insulin. Therefore the most striking difference to the previous analysis of ERK in PCOS muscle cells is our observation that insulin reduces ERK activity in vivo, rather than inducing it to even higher levels. The reasons for the discrepancy may be related to our in vivo analysis as compared with the model of cultured myotubes (see earlier). A similar discrepancy has been reported for insulin-stimulated glucose uptake and GLUT4 expression. These appear normal in cultured myotubes from PCOS muscle [44] , whereas PCOS muscle exhibits reduced glucose uptake in response to insulin in vivo [40] . Interestingly, ERK activation may influence regulation of glucose uptake in muscle [57] .
Finally, although extreme BMI has been linked to defective signalling in non-PCOS populations, multiple analyses of our data indicate that PCOS has a BMI-independent effect on insulin regulation of ERK. Our PCOS group were not overtly obese (an average BMI of 29.8 kg/m 2 ), and, although they were generally heavier than the controls, there was no significant difference in BMI between groups. Importantly there was no significant difference in ERK activation by insulin between groups when subjects were reclassified according to BMI rather than PCOS status ( Figure 5) . Moreover, the two most obese patients with PCOS were the only ones in whom insulin was able to activate ERK to any extent; in contrast, ERK was markedly up-regulated in the majority of control subjects (Figure 2A compared with  2B ). If we omitted three of the PCOS subjects to match the BMI of the groups more closely, the defective ERK signalling was still apparent in the leaner PCOS group. Therefore, although it remains likely that high BMI could worsen some molecular signalling defects, our results strongly suggest that the loss of ERK regulation in this population is due to PCOS and not BMI.
In summary, we have found compelling evidence of an abnormal insulin regulation of the Ras-ERK pathway in intact muscle from women with PCOS. This is of particular interest, as it has previously been considered that a defect in the IRS-PKB pathway was more likely to underlie the clinical development of insulin resistance. The IRS-PKB pathway is known to be vital in the regulation of glycogen synthesis, gluconeogenesis and glucose transport by insulin, and defects in this pathway have been found in animal models of T2DM as well as in some studies on human T2DM and PCOS. IRS-1 levels are reduced in T2DM, but in muscle from PCOS they are normal (Figure 4 and [40] ), whereas in isolated muscle cells IRS-1 is actually increased in PCOS [44, 46] . This may suggest distinct signalling problems in these insulin-resistant states, and it will be of interest to determine whether defects in the ERK pathway in a healthy population correlate with insulin resistance and indicate an increased risk of developing PCOS rather than T2DM.
